[Cancer Surveillance in Inflammatory Bowel Diseases].
Patients with ulcerative colitis and Crohn's colitis, especially in the presence of primary sclerosing cholangitis, have an increased risk of developing colorectal cancer due to the longstanding colonic inflammation. Therefore, anti-inflammatory drugs reduce this elevated risk.On the other hand, immunosuppressive medication can have direct mutagen effects or can lead to compromised tumor surveillance, therefore increasing the risk of extra-intestinal tumors. This article reviews recommendations concerning cancer surveillance strategies in patients with inflammatory bowel diseases.